ReviewDermatology and therapy2026
The State of the Art in Chronic Prurigo Nodularis.
Review in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic prurigo nodularis (CPN) is a highly burdensome chronic inflammatory dermatosis characterized by intensely pruritic papulonodular lesions that may persist for years. Its pathophysiology reflects a neuro-immune-fibrotic axis in which type-2 cytokines (IL-4/IL-13/IL-31), neuropeptides, and profibrotic signaling interact to sustain the itch-scratch cycle and dermal fibrosis. CPN predominantly affects older adult women and is frequently associated with dermatologic, neuropsychiatric, and cardiometabolic comorbidities. Definition, nomenclature, and management remain areas of debate, with relevant differences between European and US consensus documents. The therapeutic landscape has expanded with dupilumab and nemolizumab, the only agents currently supported by phase III evidence, whereas JAK inhibitors remain promising but investigational options that require careful safety contextualization. This narrative review synthesizes current knowledge on CPN, from definition and epidemiology to etiopathogenesis and evolving therapy, while highlighting persistent unmet needs in diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.